Phaseline

Companies › Cellectar Biosciences

Cellectar Biosciences: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Iopofosine I-131 (CLR 131)
Radiopharmaceutical; radioiodine-131-labeled lipophilic cationic compound that localizes t
–Phase 2Waldenstrom MacroglobulinemiaDec 2027
CLR 131–Phase 1High-Grade Glioma; Pediatric Solid TumorJun 2027
CLR 125
Radiopharmaceutical
–Phase 1Breast CancerFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05610891CLR 131Phase 1High-Grade GliomaOncologyJun 2027
NCT03478462CLR 131Phase 1Pediatric Solid TumorOncologyJun 2027
NCT02952508Iopofosine I-131 (CLR 131)Phase 2Waldenstrom MacroglobulinemiaOncologyDec 2027
NCT07311993CLR 125Phase 1Breast CancerOncologyFeb 2028

From the company's SEC filings

Cash of $25m on 2026-09-30; operating cash outflow about $27m a year; runway about 11 months at that burn, to Aug 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Acrivon Therapeutics Allarity Therapeutics ALX Oncology Eikon Therapeutics CNS Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.